HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goetz, C. G. Articles by Litvan, I. Search for Related Content PubMed PubMed Citation Articles by Goetz, C. G. Articles by Litvan, I. Related Collections All Clinical Neurology Clinical neurology examination All Movement Disorders Progressive supranuclear palsy

Progression of gait, speech and swallowing deficits in progressive supranuclear palsy

From the Departments of Neurological Sciences (Drs. Goetz and Leurgans) and Preventive Medicine (Dr. Leurgans), Rush University/Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL; Division of Neurology (Dr. Lang), Toronto Western Hospital and the University of Toronto, Ontario, Canada; and Cognitive Neuropharmacology Unit (Dr. Litvan), Bethesda, MD.

Address correspondence and reprint requests to Dr. Christopher G. Goetz, Suite 755, 1725 West Harrison Street, Chicago, IL 60612; e-mail: cgoetz{at}rush.edu

Objective: To identify outcome measures for clinical trials in progressive supranuclear palsy (PSP), the authors determined the time to key motor impairments in a well-defined patient cohort.

Methods: The records of consecutive patients with probable PSP, defined by National Institute of Neurological Disorders and Stroke–Society for Progressive Supranuclear Palsy workshop criteria on first visit to a tertiary care center, were selected for study if the patients were seen regularly at 3- to 6-month intervals, had at least 24 months of care at the Rush movement disorder center, and were originally seen in the movement disorder center before any of the following key motor impairments developed: unintelligible speech, no independent walking, inability to stand unassisted, wheelchair-bound, or recommendation for feeding tube placement. Using standardized criteria from the Unified Parkinson’s Disease Rating Scale and Hoehn and Yahr stages taken at each clinic visit, the authors recorded the time that each patient reached the key motor impairments and death. Median months from first symptom onset and from first consultation at the movement disorder center to each motor impairment were derived from Kaplan-Meier curves.

Results: Fifty subjects, mean age at study entry 64.2 years, were followed to death (n = 21, mean duration of surveillance 53.6 months) or in ongoing fashion (n = 29, mean duration of surveillance 46.2 months). Eighty-eight percent of the sample met at least one milestone. The median time from disease onset to the first key motor impairment was 48 months, 24 months after first consultation. The three gait items occurred temporally close, and the authors considered them thereafter as a single milestone, occurring at a median disease duration of 57 months, 34 months after first consultation. Unintelligible speech occurred at a median disease duration of 71 months, median 44 months after first consultation. As a composite end point, speech/gait accounted for 98% of the sample’s first key motor impairment. Need for nasogastric tube was rarely the first milestone (8%).

Conclusions: Gait impairment and unintelligible speech are milestones that occur rapidly in PSP and can be monitored with standardized rating scales. The authors suggest that clinical trials use these indices to assess how interventions alter anticipated progression of clinical deterioration in PSP.

This article has been cited by other articles:

				C. Zampieri and R. P Di Fabio Balance and Eye Movement Training to Improve Gait in People With Progressive Supranuclear Palsy: Quasi-Randomized Clinical Trial Physical Therapy, December 1, 2008; 88(12): 1460 - 1473. [Abstract] [Full Text] [PDF]

				N M Warren, M A Piggott, A J Lees, and D J Burn The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases J. Neurol. Neurosurg. Psychiatry, June 1, 2007; 78(6): 571 - 575. [Abstract] [Full Text] [PDF]

				L. I. Golbe and P. A. Ohman-Strickland A clinical rating scale for progressive supranuclear palsy Brain, June 1, 2007; 130(6): 1552 - 1565. [Abstract] [Full Text] [PDF]

				E. Alfonsi, M. Versino, I. M. Merlo, C. Pacchetti, E. Martignoni, G. Bertino, A. Moglia, C. Tassorelli, and G. Nappi Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes Neurology, February 20, 2007; 68(8): 583 - 589. [Abstract] [Full Text] [PDF]

				N. M Warren and D. J Burn Progressive supranuclear palsy Practical Neurology, February 1, 2007; 7(1): 16 - 23. [Full Text] [PDF]

				C. Zampieri and R. P Di Fabio Progressive Supranuclear Palsy: Disease Profile and Rehabilitation Strategies Physical Therapy, June 1, 2006; 86(6): 870 - 880. [Full Text] [PDF]

				A. Siderowf and N. P. Quinn Progressive supranuclear palsy: Setting the scene for therapeutic trials Neurology, March 25, 2003; 60(6): 892 - 893. [Full Text] [PDF]